CME Group heads into its July 22 earnings print with analysts cutting targets in unison, shorts rebuilding at a notable pace, and the stock down 10% over the past month — a rare combination of valuation reset and bearish flow for a name that usually trades quietly.
The analyst picture is the sharpest signal this week. Every firm that moved on CME over the past ten days went lower on the price target, even those holding positive ratings. Morgan Stanley trimmed to $324 from $353 while keeping Overweight. Piper Sandler cut to $295 from $329, also holding Overweight. Barclays took its target down to $270 from $316 (Equal-Weight), and UBS moved to $260 from $310 at Neutral. The pattern is uniform: bulls are staying bullish but marking down where they think the stock belongs. The consensus mean now stands near $284, roughly 16% above Monday's close of $243.61 — a gap that reflects both lingering optimism and the magnitude of recent target cuts. Raymond James was the outlier, reiterating Outperform and holding its $320 target in early July. The analyst divergence factor score of 92nd percentile confirms the Street is unusually aligned on the direction of travel, even if the conviction on ratings hasn't cracked.
The bear case centres on two familiar pressure points. Rate-cutting expectations weigh on interest rate futures volumes — the core of CME's franchise — and competitive pressure from FMX adds pricing friction on top. Against that, the bull case remains durable: 8.1% revenue growth last quarter, a 14.5% surge in the Market Data segment, and a dividend track record extending more than 14 years. The dividend factor score ranks in the 95th percentile. Price-to-earnings has compressed from above 23x thirty days ago to roughly 19.6x today — a meaningful de-rating that frames the current valuation as more digestible, even if FCF multiples remain stretched near 85x by some measures.
Short positioning adds texture to the setup, though it tells a story of incremental concern rather than outright aggression. Short interest climbed roughly 19% over the past week to 1.77% of the free float — a meaningful move in pace, yet still a low absolute level. The 30-day build has been even sharper, up around 34%, suggesting short sellers have been steadily adding since mid-June as the stock gave back its spring gains. Borrow costs have moved in the same direction, rising 47% on the week to 0.57% — elevated versus recent norms but still firmly in the cheap-to-borrow range. Availability remains essentially unconstrained: borrow supply is far deeper than demand, meaning the lending market imposes no friction on further short building if sentiment deteriorates further.
Options positioning offers no strong counterweight. The put/call ratio at 0.95 is almost exactly in line with its 20-day average of 0.95, with a z-score near zero — suggesting options traders as a whole are neither bracing for a sharp move nor positioned for a quick recovery. The 52-week PCR range runs from 0.59 to 2.05, so the current reading sits in the lower half of that band, closer to complacency than to outright fear. That neutrality may shift quickly once the July 22 print is in view; the last three earnings releases produced muted one-day reactions averaging less than 2% in absolute terms, though the June 2026 event was an exception at +4.7%.
The main event next week is Q2 results on July 22. Volume trends in interest rate futures and any guidance commentary around FMX competition will be the key variables the Street is weighing against those freshly lowered targets.
See the live data behind this article on ORTEX.
Open CME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
